Prosecution Insights
Prosecution Insights
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §112 only | 3 (38%) |
| Double-patenting + other | 3 (38%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMIREZ, DELIA M | 1 | 65.1% | +56.3% |
| LEE, JAE W | 1 | 65.6% | +39.0% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| ALLEN, SARAH ELIZABETH | 1 | 60.9% | +45.0% |
| KONOPKA, CATHERINE ANNE | 1 | 58.2% | +64.5% |
| O'BRIEN, LEA S | 1 | 51.4% | +13.9% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 60.0% | +48.2% |
| LEITH, NANCY J | 1 | 74.7% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17712864 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | VIJAYARAGHAVAN, JAGAMYA NMN | 60d overdue |
| 18453022 | CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS | OUSPENSKI, ILIA I | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17585694 | METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES | LEITH, NANCY J | 132d overdue |
| 17712864 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | VIJAYARAGHAVAN, JAGAMYA NMN | 60d overdue |
| 17998419 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | ALLEN, SARAH ELIZABETH | 72d |
| 18647877 | POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE | RAMIREZ, DELIA M | — |
| 18605188 | RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF | LEE, JAE W | — |
| 18453022 | CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS | OUSPENSKI, ILIA I | — |
| 17819227 | OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES | KONOPKA, CATHERINE ANNE | — |
| 17782607 | METHODS FOR CANCER IMMUNOTHERAPY | O'BRIEN, LEA S | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1656 | 1 |
| 1644 | 1 |
| 1637 | 1 |
| 1635 | 1 |
| 1646 | 1 |
| 1633 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647877 | POLYNUCLEOTIDES ENCODING ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR RECOGNITION SEQUENCES IN THE DYSTROPHIN GENE | RAMIREZ, DELIA M | 1652 | §112Other | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18605188 | RECOGNITION SEQUENCES FOR I-CREI-DERIVED MEGANUCLEASES AND USES THEREOF | LEE, JAE W | 1656 | §102DPOther | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18453022 | CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS | OUSPENSKI, ILIA I | 1644 | §101§112DP | Non-Final OA | — | Pending | Aug 21, 2023 |
| 17998419 | SELF-LIMITING VIRAL VECTORS ENCODING NUCLEASES | ALLEN, SARAH ELIZABETH | 1637 | §103DPOther | Non-Final OA | 72d | Pending | Nov 10, 2022 |
| 17819227 | OPTIMIZATION OF ENGINEERED MEGANUCLEASES FOR RECOGNITION SEQUENCES | KONOPKA, CATHERINE ANNE | 1635 | §112 | Non-Final OA | — | Pending | Aug 11, 2022 |
| 17782607 | METHODS FOR CANCER IMMUNOTHERAPY | O'BRIEN, LEA S | 1646 | §103DP | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17712864 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§112 | Non-Final OA | 60d overdue | Pending | Apr 04, 2022 |
| 17585694 | METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES | LEITH, NANCY J | 1636 | §112Other | Non-Final OA | 132d overdue | Pending | Jan 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial